Drug intelligence / Profile preview

Jurona virus

Development stage: Preclinical
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

Jurona virus (JURV) is a novel oncolytic virus belonging to the Vesiculovirus genus, characterized by its tumor selectivity, fast kinetics, low seroprevalence, and minimal toxicity in humans. It functions as an immunotherapeutic agent by inducing tumor regression and modulating the tumor microenvironment to activate immune effectors. This leads to a state conducive to anti-tumor activity, and JURV has demonstrated synergy with anti-PD-1 therapy in preclinical models of hepatocellular carcinoma, improving survival rates.

Beyond the preview

Go deeper on Jurona virus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jurona virus.

Explore the full profile